icam5 coating capture antibodies Search Results


polyclonal anti human icam 1 capture ab  (R&D Systems)
90
R&D Systems polyclonal anti human icam 1 capture ab
Polyclonal Anti Human Icam 1 Capture Ab, supplied by R&D Systems, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/icam5+coating+capture+antibodies/Human+ICAM-5+Antibody/pmc02815248-184-11-16
Average 90 stars, based on 1 article reviews
polyclonal anti human icam 1 capture ab - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier
protein g affinity purified mouse monoclonal anti human sicam5 antibody  (R&D Systems)
93
R&D Systems protein g affinity purified mouse monoclonal anti human sicam5 antibody
Assay of <t>sICAM5</t> in plasma from epilepsy patients and controls . (A) Dot-plot of sICAM5 concentrations in plasma (square, patients; diamond, controls). For values between the horizontal lines, the assay does not accurately discriminate between patients and controls. (B) Bar graph and error calculation for data in Part (A) . Difference is significant for p = 0.002. (C) ROC curve for data in Part a, showing an area under the curve (AUC) value of 0.87.
Protein G Affinity Purified Mouse Monoclonal Anti Human Sicam5 Antibody, supplied by R&D Systems, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/icam5+coating+capture+antibodies/Human+ICAM-5+Antibody/pmc03535822-73-5-16
Average 93 stars, based on 1 article reviews
protein g affinity purified mouse monoclonal anti human sicam5 antibody - by Bioz Stars, 2026-09
93/100 stars
  Buy from Supplier
polyclonal antihuman icam 1 capture ab  (R&D Systems)
93
R&D Systems polyclonal antihuman icam 1 capture ab
Assay of <t>sICAM5</t> in plasma from epilepsy patients and controls . (A) Dot-plot of sICAM5 concentrations in plasma (square, patients; diamond, controls). For values between the horizontal lines, the assay does not accurately discriminate between patients and controls. (B) Bar graph and error calculation for data in Part (A) . Difference is significant for p = 0.002. (C) ROC curve for data in Part a, showing an area under the curve (AUC) value of 0.87.
Polyclonal Antihuman Icam 1 Capture Ab, supplied by R&D Systems, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/icam5+coating+capture+antibodies/Human+ICAM-5+Antibody/10__1097_slash_rli__0b013e3181ee5bdd-53-19-24
Average 93 stars, based on 1 article reviews
polyclonal antihuman icam 1 capture ab - by Bioz Stars, 2026-09
93/100 stars
  Buy from Supplier
icam5 coating capture antibodies  (R&D Systems)
93
R&D Systems icam5 coating capture antibodies
Assay of <t>sICAM5</t> in plasma from epilepsy patients and controls . (A) Dot-plot of sICAM5 concentrations in plasma (square, patients; diamond, controls). For values between the horizontal lines, the assay does not accurately discriminate between patients and controls. (B) Bar graph and error calculation for data in Part (A) . Difference is significant for p = 0.002. (C) ROC curve for data in Part a, showing an area under the curve (AUC) value of 0.87.
Icam5 Coating Capture Antibodies, supplied by R&D Systems, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/icam5+coating+capture+antibodies/Human+ICAM-5+Antibody/us11598782-369-0-6
Average 93 stars, based on 1 article reviews
icam5 coating capture antibodies - by Bioz Stars, 2026-09
93/100 stars
  Buy from Supplier

Image Search Results


Assay of sICAM5 in plasma from epilepsy patients and controls . (A) Dot-plot of sICAM5 concentrations in plasma (square, patients; diamond, controls). For values between the horizontal lines, the assay does not accurately discriminate between patients and controls. (B) Bar graph and error calculation for data in Part (A) . Difference is significant for p = 0.002. (C) ROC curve for data in Part a, showing an area under the curve (AUC) value of 0.87.

Journal: Frontiers in Neurology

Article Title: The TARC/sICAM5 Ratio in Patient Plasma is a Candidate Biomarker for Drug Resistant Epilepsy

doi: 10.3389/fneur.2012.00181

Figure Lengend Snippet: Assay of sICAM5 in plasma from epilepsy patients and controls . (A) Dot-plot of sICAM5 concentrations in plasma (square, patients; diamond, controls). For values between the horizontal lines, the assay does not accurately discriminate between patients and controls. (B) Bar graph and error calculation for data in Part (A) . Difference is significant for p = 0.002. (C) ROC curve for data in Part a, showing an area under the curve (AUC) value of 0.87.

Article Snippet: Wells were coated overnight with protein G affinity purified mouse monoclonal anti-human sICAM5 antibody (capture antibody; R&D Systems, Minneapolis, MN, USA; catalog # MAB 1950), 2 μg/mL diluted in phosphate buffered saline (PBS; 25 μL/well).

Techniques: Clinical Proteomics

Levels of cytokines and chemokines in plasma that significantly distinguish between epilepsy patients and controls .

Journal: Frontiers in Neurology

Article Title: The TARC/sICAM5 Ratio in Patient Plasma is a Candidate Biomarker for Drug Resistant Epilepsy

doi: 10.3389/fneur.2012.00181

Figure Lengend Snippet: Levels of cytokines and chemokines in plasma that significantly distinguish between epilepsy patients and controls .

Article Snippet: Wells were coated overnight with protein G affinity purified mouse monoclonal anti-human sICAM5 antibody (capture antibody; R&D Systems, Minneapolis, MN, USA; catalog # MAB 1950), 2 μg/mL diluted in phosphate buffered saline (PBS; 25 μL/well).

Techniques: Clinical Proteomics, Concentration Assay

IL-6/sICAM5 ratio in plasma from epilepsy patients and controls . (A) Dot-plot of IL-6/sICAM5 concentrations in plasma (square, patients; diamond, controls). For values between the horizontal lines, the assay does not accurately discriminate between patients and controls. (B) Bar graph and error calculation for data in Part (A) . Difference is not significant, with p = 0.087. (C) ROC curve for data in Part (A) , showing an area under the curve (AUC) value of 0.90.

Journal: Frontiers in Neurology

Article Title: The TARC/sICAM5 Ratio in Patient Plasma is a Candidate Biomarker for Drug Resistant Epilepsy

doi: 10.3389/fneur.2012.00181

Figure Lengend Snippet: IL-6/sICAM5 ratio in plasma from epilepsy patients and controls . (A) Dot-plot of IL-6/sICAM5 concentrations in plasma (square, patients; diamond, controls). For values between the horizontal lines, the assay does not accurately discriminate between patients and controls. (B) Bar graph and error calculation for data in Part (A) . Difference is not significant, with p = 0.087. (C) ROC curve for data in Part (A) , showing an area under the curve (AUC) value of 0.90.

Article Snippet: Wells were coated overnight with protein G affinity purified mouse monoclonal anti-human sICAM5 antibody (capture antibody; R&D Systems, Minneapolis, MN, USA; catalog # MAB 1950), 2 μg/mL diluted in phosphate buffered saline (PBS; 25 μL/well).

Techniques: Clinical Proteomics

IL-8/sICAM5 ratio in plasma from epilepsy patients and controls . (A) Dot-plot of IL-8/sICAM5 concentrations in plasma (square, patients; diamond, controls). For values between the horizontal lines, the assay does not accurately discriminate between patients and controls. (B) Bar graph and error calculation for data in Part (A) . Difference not significant, with p = 0.125. (C) ROC curve for data in Part (A) , showing an area under the curve (AUC) value of 0.88.

Journal: Frontiers in Neurology

Article Title: The TARC/sICAM5 Ratio in Patient Plasma is a Candidate Biomarker for Drug Resistant Epilepsy

doi: 10.3389/fneur.2012.00181

Figure Lengend Snippet: IL-8/sICAM5 ratio in plasma from epilepsy patients and controls . (A) Dot-plot of IL-8/sICAM5 concentrations in plasma (square, patients; diamond, controls). For values between the horizontal lines, the assay does not accurately discriminate between patients and controls. (B) Bar graph and error calculation for data in Part (A) . Difference not significant, with p = 0.125. (C) ROC curve for data in Part (A) , showing an area under the curve (AUC) value of 0.88.

Article Snippet: Wells were coated overnight with protein G affinity purified mouse monoclonal anti-human sICAM5 antibody (capture antibody; R&D Systems, Minneapolis, MN, USA; catalog # MAB 1950), 2 μg/mL diluted in phosphate buffered saline (PBS; 25 μL/well).

Techniques: Clinical Proteomics

TARC/sICAM5 ratio in plasma from epilepsy patients and controls . (A) Dot-plot of TARC/sICAM5 concentrations in plasma (square, patients; diamond, controls). There are no values between the horizontal lines, indicating the assay accurately discriminates between patients and controls. (B) Bar graph and error calculation for data in Part (A) . Difference is 13-fold, and is significant for p = 0.034. (C) ROC curve for data in Part (A) , showing an area under the curve (AUC) value of 1.00.

Journal: Frontiers in Neurology

Article Title: The TARC/sICAM5 Ratio in Patient Plasma is a Candidate Biomarker for Drug Resistant Epilepsy

doi: 10.3389/fneur.2012.00181

Figure Lengend Snippet: TARC/sICAM5 ratio in plasma from epilepsy patients and controls . (A) Dot-plot of TARC/sICAM5 concentrations in plasma (square, patients; diamond, controls). There are no values between the horizontal lines, indicating the assay accurately discriminates between patients and controls. (B) Bar graph and error calculation for data in Part (A) . Difference is 13-fold, and is significant for p = 0.034. (C) ROC curve for data in Part (A) , showing an area under the curve (AUC) value of 1.00.

Article Snippet: Wells were coated overnight with protein G affinity purified mouse monoclonal anti-human sICAM5 antibody (capture antibody; R&D Systems, Minneapolis, MN, USA; catalog # MAB 1950), 2 μg/mL diluted in phosphate buffered saline (PBS; 25 μL/well).

Techniques: Clinical Proteomics